Cytox Company

Cytox has developed a simple genetic-based non-invasive blood test to assess the risk and diagnosis of Alzheimer's Disease in the early stages. The company's approaches are being actively evaluated today by global pharma, biotech and sponsors of more extensive cohort studies as a more rigorous and cost-effective means to improve stratification of at-risk subjects for participation in clinical trials. The company has two products: genoSCORE-LAB and genoTOR that use blood and saliva, so they are non-invasive, and can be used anywhere globally, on a mass scale, without excessive costs associated with current diagnostic approaches requiring highly specialised PET imaging facilities. Cytox appointed Yourgene Genomic Services (part of Yourgene Health) at the end of 2020 as a Beta testing clinical laboratory partner for genoSCORE-LAB. Patient-facing clinicians can use genoSCORE-LAB to assess patients for the risk of developing Alzheimer's before symptoms arise, before invasive cerebrospinal fluid testing or expensive scanning techniques.
Industry: Diagnostics
Headquarters: Manchester, United Kingdom
Founded Date: 2004
Employees Number: 1-10
Funding Status: Early Stage Venture
Investors Number: 15
Total Funding: £13 584 798
Estimated Revenue: £780 000 - £7 800 000
Last Funding Date: 01-01-2019
Last Funding Type: Grant

Visit Website
enquiries@cytoxgroup.com
http://twitter.com/CytoxDx
Register and Claim Ownership